HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Abstract
Individuals with severe factor VIII deficiency experience recurrent hemorrhages and develop progressive joint damage. Large retrospective, nonrandomized studies of patient cohorts followed over decades show that factor prophylaxis initiated at an early age before the onset of recurrent bleeding reduces the incidence of hemophilic arthropathy. Two recent prospective, multicenter, randomized trials conducted in Europe (the ESPRIT study) and the USA (the Joint Outcome Study) confirm the efficacy of prophylaxis in the prevention of hemarthroses and arthropathy. Regular prophylaxis initiated in early childhood enhances the quality of life for patients with severe hemophilia and reduces the risk of inhibitor development. The substantial costs of such preventative therapy may be offset by the reduced expenditures that the care of degenerative joint disease in adult hemophilia patients would otherwise require.
AuthorsHans-Christoph Rossbach
JournalVascular health and risk management (Vasc Health Risk Manag) Vol. 6 Pg. 59-68 ( 2010) ISSN: 1178-2048 [Electronic] New Zealand
PMID20234780 (Publication Type: Journal Article, Review)
Chemical References
  • Coagulants
  • Factor VIII
Topics
  • Adolescent
  • Adult
  • Child
  • Coagulants (administration & dosage, antagonists & inhibitors)
  • Factor VIII (administration & dosage, physiology)
  • Hemarthrosis (prevention & control)
  • Hemophilia A (complications)
  • Hemorrhage (prevention & control)
  • Humans
  • Joint Diseases (prevention & control)
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD